Samsung BIOEPIS set a new sales record in a year

Sales of 271 billion won in the 3rd quarter

It increased by 14% compared to the previous year

Lucentis-similar. Additional milestones are introduced from overseas

Samsung BIOEPIS has generated the largest quarterly sales since its launch.

 

Overseas sales of biosimilars have increased, and milestones have flowed in due to overseas permits for subsequent biosimilar products.

 

According to the Financial Supervisory Service on the 23rd, SAMSUNG BIOEPIS saw its sales rise 14.4% year-on-year to 271 billion won in the third quarter.

 

It surpassed the previous maximum sales of 236.9 billion won recorded in the third quarter of last year in a year, breaking a new quarterly sales record.

 

The company's cumulative sales in the third quarter were 625.2 billion won, up 9.2% from the previous year.

 

Samsung Bioepis

Most of Samsung BIOEPIS sales are generated through overseas sales of its own biosimilar products.

 

SAMSUNG BIOEPIS succeeded in commercializing biosimilars of six products, including Enbrel, Remicade, Herceptin, Humira, Avastin and Lucentis.

 

In Europe, all six products were approved, and in the United States, five products excluding Avastin were approved for sale.

 

SAMSUNG BIOEPIS's performance has slowed slightly as sales have been on the decline for the second consecutive quarter since the third quarter of last year.

 

Sales in the first quarter of this year amounted to KRW 166.7 billion, down 29.6% from the third quarter of last year.

 

With the aim of securing inventory in preparation for the prolonged COVID-19, pre-orders from hospitals and wholesalers in Europe have recovered their performance.

 

However, it rebounded in the second quarter and broke a new sales record in the third quarter, recovering from the sluggishness caused by COVID-19.

 

Overseas sales sold by Biogen and Organon showed growth.

 

Samsung Bioepis biosimilar's overseas sales in the third quarter were $342.8 million (about 406 billion won), up 11% from $369.9 million a year earlier.

 

SAMSUNG BIOEPIS is selling five biosimilars in global markets excluding Korea through marketing partnerships with Biogen and Organon.

 

Quarterly SAMSUNG BIOEPIS sales (unit: 1 million won, data: Financial Supervisory Service)

Biogen is in charge of distributing and selling three types of autoimmune disease treatments in Europe, including Enbrel biosimilar Benepali, Remicaid biosimilar Flixabi, and Humira biosimilar Imraldi.

 

Organon (formerly MSD) sells these three products under the product names Renflexis (Remicade biosimilar), Brenzys (Enbrel biosimilar), and Hadlima (Humira biosimilar) in the rest of the world except the United States, Korea, and China.

 

Organon is also in charge of overseas sales of two types of anticancer drugs, Herceptin biosimilar Ontruzant and Avastin biosimilar Aybintio.

 

Sales of biosimilars sold by Biogen reached $22.8 million in the third quarter, up 2% from the previous year.

 

Organon's biosimilar sales in the third quarter rose 41% year-on-year to $140 million.

 

The combined sales of biosimilars sold by Biogen and Organon in the third quarter amounted to $916.2 million (about 1.8 trillion won), up 11% from the previous year.

 

In the third quarter, additional milestones were also introduced with the overseas approval of biosimilars.

 

Lucentis biosimilar Byooviz, developed by Samsung Bioepis in August, was approved for sale by the European Commission (EC), and a month later, it was approved by the U.S.

 

Food and Drug Administration (FDA).